Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Plasma cell 2Classical hematology 2Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Oligodendroglioma 1Glioma 1Astrocytoma 1

Interventions

Temozolomide 79Magnetic Resonance Spectroscopy 68Specimen Handling 45Radiotherapy 42Bevacizumab 29Radiosurgery 27Cyclophosphamide 27Radiation 20pembrolizumab 19Blood Specimen Collection 19fludarabine 16Nivolumab 16Irinotecan 15Carboplatin 13Biopsy 13Etoposide 12Vincristine 11Pemetrexed 11Lomustine 11dinutuximab 9Surgical Procedures, Operative 9trametinib 8abemaciclib 8Ipilimumab 8naxitamab 7fluciclovine F-18 7Watchful Waiting 7Topotecan 7Proton Therapy 7Magnetic Resonance Imaging 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Tretinoin × CNS × Clear all
NCT05345002 2026-02-20

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
55 enrolled
CNS

Astrocytoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡